Bristol Myers Squibb launches Kopozgo (Mavacamten) in India for obstructive hypertrophic… EP News Bureau Oct 13, 2025 Kopozgo is the first and only oral cardiac myosin inhibitor approved in India for treating adults with symptomatic obstructive…
